Ruth Plummer

27PUBLICATIONS

271CO-AUTHORS

AutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersLiquid biopsies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (27)

Sort by Publication Date:

|May 23, 2026

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

|May 21, 2026

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

|May 13, 2026

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Feb 10, 2026

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.

Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher

|Jan 21, 2026

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

Pageof 5

Frequent Collaborators

Timothy A Yap

Elisa Fontana

Udai Banerji

Hans Prenen

Elena Garralda

Juanita S Lopez

Geoffrey I Shapiro

Johann S de Bono

Victor Moreno

Sarah P Blagden

Frequent Collaborators

Timothy A Yap

Elisa Fontana

Udai Banerji

Hans Prenen